Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
Earnings Data
Report Date
May 18, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.51Last Year’s EPS
2.09Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q4 2025
Earnings Call Date:Mar 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.Company Guidance
Completed $60 million Private Financing
Announced a private financing providing up to $60.0M in potential gross proceeds (including $10M upfront). Structure includes milestone-based Series A ($10M), Series B ($10M) and a Series C common warrant ($30M, 3-year term) with an accelerated feature if stock trades at 2x the deal price for 30 consecutive days.
Tivoxavir Development Progress — Preclinical and Formulation Gains
Preclinical data show robust activity across influenza A and B and single-dose protection against lethal bird flu in three species with significant reductions in lung viral burden. A next-generation compressed tablet formulation demonstrated ~30% increased exposure in preclinical studies, supporting potential 28-day coverage for a once-monthly prophylactic regimen.
Planned Human Challenge Trial (U.K.) and Australian Bridging Study
Intend to initiate a Phase IIa seasonal influenza prophylaxis human challenge study at hVIVO in the U.K. starting in June, pending MHRA approval. A Phase I bridging study in Australia to confirm extended exposure is underway and has been approved without flagged concerns.
Improved Reported Financial Results (Year-ended Dec 31, 2025)
Reported net income of $9.2M ($0.83 basic / $0.82 diluted) in 2025 versus a net loss of $166.5M in 2024. Revenue increased to $2.8M in 2025 from $0.226M in 2024 (≈+1139%), driven primarily by the recognition of $2.7M deferred revenue related to a mutual termination of an oncology licensing agreement.
Expense Reductions
Research & development expense declined modestly to $12.1M in 2025 from $12.8M in 2024 (≈-5.5%). General & administrative expense decreased to $8.5M from $12.3M (≈-30.9%), primarily from lower professional and consulting fees.
TRAW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TRAW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $1.99 | $2.02 | +1.51% |
Nov 13, 2025 | $2.14 | $1.77 | -17.29% |
Aug 14, 2025 | $1.64 | $1.62 | -1.22% |
May 15, 2025 | $1.24 | $1.10 | -11.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Traws Pharma (TRAW) report earnings?
Traws Pharma (TRAW) is schdueled to report earning on May 18, 2026, Before Open (Confirmed).
What is Traws Pharma (TRAW) earnings time?
Traws Pharma (TRAW) earnings time is at May 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRAW EPS forecast?
TRAW EPS forecast for the fiscal quarter 2026 (Q1) is -0.51.